Human primary liver cancer organoids reveal intratumor and interpatient drug response heterogeneity

Ling Li, Hildur Knutsdottir, Ken Hui, Matthew J. Weiss, Jin He, Benjamin Philosophe, Andrew M. Cameron, Christopher L. Wolfgang, Timothy M. Pawlik, Gabriel Ghiaur, Andrew J. Ewald, Esteban Mezey, Joel S. Bader, Florin M. Selaru

Research output: Contribution to journalArticle

Abstract

Liver cancer is the fourth leading cause of cancer-related mortality and is distinguished by a relative paucity of chemotherapy options. It has been hypothesized that intratumor genetic heterogeneity may contribute to the high failure rate of chemotherapy. Here, we evaluated functional heterogeneity in a cohort of primary human liver cancer organoid lines. Each primary human liver cancer surgical specimen was used to generate multiple cancer organoid lines, obtained from distinct regions of the tumor. A total of 27 liver cancer lines were established and tested with 129 cancer drugs, generating 3,483 cell survival data points. We found a rich intratumor, functional (drug response) heterogeneity in our liver cancer patients. Furthermore, we established that the majority of drugs were either ineffective, or effective only in select organoid lines. In contrast, we found that a subset of drugs appeared pan-effective, displaying at least moderate activity in the majority of these cancer organoid lines. These drugs, which are FDA approved for indications other than liver cancers, deserve further consideration as either systemic or local therapeutics. Of note, molecular profiles, obtained for a reduced sample set, did not correlate with the drug response heterogeneity of liver cancer organoid lines. Taken together, these findings lay the foundation for in-depth studies of pan-effective drugs, as well as for functional personalized oncology approaches. Lastly, these functional studies demonstrate the utility of cancer organoid drug testing as part of a drug discovery pipeline.

Original languageEnglish (US)
Article numberY
JournalJCI Insight
Volume4
Issue number2
DOIs
StatePublished - Jan 24 2019

Fingerprint

Organoids
Liver Neoplasms
Pharmaceutical Preparations
Neoplasms
Drug Therapy
Genetic Heterogeneity
Drug Discovery
Cell Survival
Mortality

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Human primary liver cancer organoids reveal intratumor and interpatient drug response heterogeneity. / Li, Ling; Knutsdottir, Hildur; Hui, Ken; Weiss, Matthew J.; He, Jin; Philosophe, Benjamin; Cameron, Andrew M.; Wolfgang, Christopher L.; Pawlik, Timothy M.; Ghiaur, Gabriel; Ewald, Andrew J.; Mezey, Esteban; Bader, Joel S.; Selaru, Florin M.

In: JCI Insight, Vol. 4, No. 2, Y, 24.01.2019.

Research output: Contribution to journalArticle

@article{df4877cebf414600aa21deb11c648f36,
title = "Human primary liver cancer organoids reveal intratumor and interpatient drug response heterogeneity",
abstract = "Liver cancer is the fourth leading cause of cancer-related mortality and is distinguished by a relative paucity of chemotherapy options. It has been hypothesized that intratumor genetic heterogeneity may contribute to the high failure rate of chemotherapy. Here, we evaluated functional heterogeneity in a cohort of primary human liver cancer organoid lines. Each primary human liver cancer surgical specimen was used to generate multiple cancer organoid lines, obtained from distinct regions of the tumor. A total of 27 liver cancer lines were established and tested with 129 cancer drugs, generating 3,483 cell survival data points. We found a rich intratumor, functional (drug response) heterogeneity in our liver cancer patients. Furthermore, we established that the majority of drugs were either ineffective, or effective only in select organoid lines. In contrast, we found that a subset of drugs appeared pan-effective, displaying at least moderate activity in the majority of these cancer organoid lines. These drugs, which are FDA approved for indications other than liver cancers, deserve further consideration as either systemic or local therapeutics. Of note, molecular profiles, obtained for a reduced sample set, did not correlate with the drug response heterogeneity of liver cancer organoid lines. Taken together, these findings lay the foundation for in-depth studies of pan-effective drugs, as well as for functional personalized oncology approaches. Lastly, these functional studies demonstrate the utility of cancer organoid drug testing as part of a drug discovery pipeline.",
author = "Ling Li and Hildur Knutsdottir and Ken Hui and Weiss, {Matthew J.} and Jin He and Benjamin Philosophe and Cameron, {Andrew M.} and Wolfgang, {Christopher L.} and Pawlik, {Timothy M.} and Gabriel Ghiaur and Ewald, {Andrew J.} and Esteban Mezey and Bader, {Joel S.} and Selaru, {Florin M.}",
year = "2019",
month = "1",
day = "24",
doi = "10.1172/jci.insight.121490",
language = "English (US)",
volume = "4",
journal = "JCI insight",
issn = "2379-3708",
publisher = "The American Society for Clinical Investigation",
number = "2",

}

TY - JOUR

T1 - Human primary liver cancer organoids reveal intratumor and interpatient drug response heterogeneity

AU - Li, Ling

AU - Knutsdottir, Hildur

AU - Hui, Ken

AU - Weiss, Matthew J.

AU - He, Jin

AU - Philosophe, Benjamin

AU - Cameron, Andrew M.

AU - Wolfgang, Christopher L.

AU - Pawlik, Timothy M.

AU - Ghiaur, Gabriel

AU - Ewald, Andrew J.

AU - Mezey, Esteban

AU - Bader, Joel S.

AU - Selaru, Florin M.

PY - 2019/1/24

Y1 - 2019/1/24

N2 - Liver cancer is the fourth leading cause of cancer-related mortality and is distinguished by a relative paucity of chemotherapy options. It has been hypothesized that intratumor genetic heterogeneity may contribute to the high failure rate of chemotherapy. Here, we evaluated functional heterogeneity in a cohort of primary human liver cancer organoid lines. Each primary human liver cancer surgical specimen was used to generate multiple cancer organoid lines, obtained from distinct regions of the tumor. A total of 27 liver cancer lines were established and tested with 129 cancer drugs, generating 3,483 cell survival data points. We found a rich intratumor, functional (drug response) heterogeneity in our liver cancer patients. Furthermore, we established that the majority of drugs were either ineffective, or effective only in select organoid lines. In contrast, we found that a subset of drugs appeared pan-effective, displaying at least moderate activity in the majority of these cancer organoid lines. These drugs, which are FDA approved for indications other than liver cancers, deserve further consideration as either systemic or local therapeutics. Of note, molecular profiles, obtained for a reduced sample set, did not correlate with the drug response heterogeneity of liver cancer organoid lines. Taken together, these findings lay the foundation for in-depth studies of pan-effective drugs, as well as for functional personalized oncology approaches. Lastly, these functional studies demonstrate the utility of cancer organoid drug testing as part of a drug discovery pipeline.

AB - Liver cancer is the fourth leading cause of cancer-related mortality and is distinguished by a relative paucity of chemotherapy options. It has been hypothesized that intratumor genetic heterogeneity may contribute to the high failure rate of chemotherapy. Here, we evaluated functional heterogeneity in a cohort of primary human liver cancer organoid lines. Each primary human liver cancer surgical specimen was used to generate multiple cancer organoid lines, obtained from distinct regions of the tumor. A total of 27 liver cancer lines were established and tested with 129 cancer drugs, generating 3,483 cell survival data points. We found a rich intratumor, functional (drug response) heterogeneity in our liver cancer patients. Furthermore, we established that the majority of drugs were either ineffective, or effective only in select organoid lines. In contrast, we found that a subset of drugs appeared pan-effective, displaying at least moderate activity in the majority of these cancer organoid lines. These drugs, which are FDA approved for indications other than liver cancers, deserve further consideration as either systemic or local therapeutics. Of note, molecular profiles, obtained for a reduced sample set, did not correlate with the drug response heterogeneity of liver cancer organoid lines. Taken together, these findings lay the foundation for in-depth studies of pan-effective drugs, as well as for functional personalized oncology approaches. Lastly, these functional studies demonstrate the utility of cancer organoid drug testing as part of a drug discovery pipeline.

UR - http://www.scopus.com/inward/record.url?scp=85070658357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070658357&partnerID=8YFLogxK

U2 - 10.1172/jci.insight.121490

DO - 10.1172/jci.insight.121490

M3 - Article

C2 - 30674722

AN - SCOPUS:85070658357

VL - 4

JO - JCI insight

JF - JCI insight

SN - 2379-3708

IS - 2

M1 - Y

ER -